98%
921
2 minutes
20
The "biological view" of Alzheimer's disease (AD) focuses on the role of plaques and tangles and excludes syndromes from the disease definition. However, cognitive syndromes are fundamental aspects of AD and are the ultimate target of treatments. Accordingly, the study of cognitive syndromes should remain a major goal of AD research. We questioned how well the idea of excluding cognitive syndromes from the definition of AD is scientifically supported. In this regard, we believe that the "biological view" of AD is sustainable if a close relationship between plaques and tangles and cognitive disorders is discovered. A simple way to preliminarily investigate the strength of this relationship is to test whether the study of plaques and tangles allows us to make predictions about the characteristics of cognitive impairment. For this purpose, we summarized the main data from the literature on the predictions that can be made about cognitive impairment from the study of plaques and tangles in AD. The results showed that although plaques precede cognitive symptoms, most people with plaques do not develop cognitive deficits, and the association between plaque distribution and clinical features is weak. Tangles have a stronger association with the presence and severity of cognitive decline, but this is because tau protein involvement is a more terminal event, occurring as a result of neuronal loss. Overall, the predictions that can be made about the main features of the cognitive picture from the study of plaques and tangles still appear limited and imprecise.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/13872877251374319 | DOI Listing |
J Alzheimers Dis
September 2025
IRCCS Fondazione Don Carlo Gnocchi ONLUS, Milan, Italy.
The "biological view" of Alzheimer's disease (AD) focuses on the role of plaques and tangles and excludes syndromes from the disease definition. However, cognitive syndromes are fundamental aspects of AD and are the ultimate target of treatments. Accordingly, the study of cognitive syndromes should remain a major goal of AD research.
View Article and Find Full Text PDFPsychogeriatrics
September 2025
Clinical Neurosciences and Mental Health Department, Faculty of Medicine of Porto University, Porto, Portugal.
The dopaminergic system may be at the base of some neurobehavioral symptoms, as apathy and depression, and extrapyramidal symptoms, often seen in Alzheimer's disease patients. It can also have an impact on cognitive decline, as extrapyramidal symptoms, classically linked with dopamine dysfunction, are associated with increased risk of cognitive impairment and Alzheimer's disease progression. We review the knowledge of the dopaminergic system, emphasizing changes in Alzheimer's disease.
View Article and Find Full Text PDFACS Sens
September 2025
Department of Pharmacy, The People's Hospital of Guangxi Zhuang Autonomous Region & Guangxi Academy of Medical Sciences, Nanning, Guangxi 530021, China.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder primarily characterized by cognitive decline and behavioral impairments, typically manifesting in the elderly and presenile population. With the rapid global aging trend, early diagnosis and treatment of AD have become increasingly urgent research priorities. The primary pathological features of AD include excessive accumulation of β-amyloid (Aβ) plaques, the formation of neurofibrillary tangles, and neuronal loss.
View Article and Find Full Text PDFACS Chem Neurosci
September 2025
Institute of Cell Engineering, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21215, United States.
Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive impairment and neuronal loss, with pathological hallmarks including Aβ plaque deposition and tau tangles. At present, the early diagnosis and treatment of AD still face great challenges, such as limited diagnostic methods, difficulty in blood-brain barrier (BBB) penetration, complex disease mechanisms, and lack of highly effective targeted therapies. Antibody drugs have shown broad prospects in the field of AD due to their high specificity, engineering and multifunctional therapeutic potential, include targeted Aβ clearance, tau pathological regulation, imaging probes, and blood biomarkers.
View Article and Find Full Text PDFCurr Alzheimer Res
September 2025
Department of Biochemistry, General Medicine Practice Program, Batterjee Medical College, Jeddah, Saudi Arabia.
A serine/threonine kinase with a wide variety of substrates, Glycogen Synthase Kinase-3 (GSK-3) is widely expressed. GSK-3 is a key player in cell metabolism and signaling, modulating numerous cellular functions and playing significant roles in both healthy and diseased states. The two histopathological features of Alzheimer's disease, the intracellular neurofibrillary tangles composed of hyperphosphorylated tau, and the extracellular senile plaques composed of beta-amyloid, have been linked to GSK-3.
View Article and Find Full Text PDF